Certara (CERT) Osake Kurssi

Certara Inc operates with a business model focused on providing solutions and services to support the entire drug development process. As a leading provider of biosimulation software and technology, Certara integrates quantitative methods and software applications to help pharmaceutical and biotechnology companies optimize development and improve drug safety. With a strong focus on precision medicine and personalized therapies, Certara combines scientific expertise with advanced technology to facilitate decision-making in clinical and regulatory activities. Their comprehensive suite of tools and services enables clients to streamline drug development, predict drug outcomes, and ultimately bring safer and more effective medicines to market efficiently.

Certara Inc is primarily active in the pharmaceutical and biotechnology industries.

Certara Inc is a leading provider of model-informed drug development and regulatory science solutions. Founded in 2008, Certara has constantly evolved and grown, becoming a trusted partner to more than 1,500 biopharmaceutical companies and academic institutions. Certara's innovative software and services help improve the efficiency and success of drug development, reducing costs and timeframes. With a team of highly experienced scientists and industry experts, Certara combines cutting-edge technology with deep domain knowledge to facilitate informed decision-making throughout the drug development process. Certara's commitment to excellence has enabled it to establish a strong presence globally, making it a highly respected and influential player in the pharmaceutical industry.

Certara Inc has achieved several significant milestones throughout its history. Some noteworthy achievements include the acquisition of Simcyp Limited, a leading provider of physiologically-based pharmacokinetic modeling and simulation services. This acquisition has strengthened Certara's position as a global leader in modeling and simulation software and has expanded its reach in the pharmaceutical industry. Additionally, Certara has collaborated with key industry stakeholders to develop innovative solutions for drug development and optimization, further contributing to its reputation as a trusted partner in pharmaceutical sciences. The company's commitment to research, technological advancements, and strategic partnerships has propelled Certara Inc towards continuous growth and success.

Certara Inc is primarily present in multiple countries and regions around the world. With a global presence, the company operates in North America, Europe, Asia-Pacific, and Latin America. It has established offices and collaborations in various key pharmaceutical and biotechnology hubs, including the United States, United Kingdom, Germany, France, Japan, China, and Brazil. Certara's extensive international reach allows it to serve a diverse clientele and partner with industry leaders across different geographical locations, further strengthening its position as a leading provider of scientific software and services in the life sciences industry.

Certara Inc represents a strong commitment to scientific excellence and innovation, striving to bridge the gap between discovery and application. The company values collaborative partnerships, with a focus on providing cutting-edge solutions to support informed decision-making in drug development and regulatory processes. Certara fosters a culture of integrity and transparency, aiming to deliver value to its clients and stakeholders while improving patient outcomes. With its advanced technology platforms and expert-driven approaches, Certara empowers researchers and drug developers to optimize drug discovery and development, ensuring safer and more effective therapies for patients worldwide.

Analyytikot asettavat tällä hetkellä Certara-osakkeelle keskimääräisen tavoitehinnan 8,50 USD (mediaani: 8,00 USD), mikä merkitsee −11,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 19 analyytikkoarvioon.

Certara Analyytikkojen kursstavoitteet 2026

19 analyytikkoa arvioi tällä hetkellä Certara-osaketta: 10 suosittaa ostoa, 9 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Certara-yhtiöltä 379,66 M USD liikevaihtoa ja 0,34 USD osakekohtaista tulosta.

Certara Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Certara-osake noteerataan hintaan 8,51 EUR (9,57 USD).

Certara-osake (CERT) on listattuna 2 pörssissä, muun muassa: NASDAQ (CERT), Hamburg (700.HM).

Certara Inc is a leading company in the field of biosimulation and technology platforms for drug development. The company offers a wide range of products and services to support its customers in developing, testing, and bringing safer and more effective drugs to market. Certara's business model includes three main divisions: Modelling & Simulation, Regulatory Science, and Clinical Pharmacology. Each of these divisions offers specialized services and products to meet the needs of different customers in the healthcare industry. Modelling & Simulation is an important division of Certara, based on the application of biosimulation and modeling techniques to support drug research and development activities. This division specializes in providing knowledge in modeling and simulation methods and developing software products to help evaluate and optimize the effectiveness and safety of drugs. The Regulatory Science division is focused on promoting collaborations with regulatory authorities in the evaluation of drug products. This division works with pharmaceutical companies and authorities to ensure that drug products meet all necessary regulatory requirements and that their safety and efficacy are ensured during clinical trials and use. Certara's Clinical Pharmacology division specializes in developing strategies to optimize the clinical effectiveness of drugs through clinical pharmacology and bioanalysis phases. Additionally, this division also develops behavioral diagnostic tools and innovative technologies to optimize drug selection and patient treatment. Certara also offers a variety of products tailored to customer needs, including simulation tools, analysis tools, databases, and software packages for drug development. Some of the most commonly used products are the D360 platform and the physiology platform (PK/PD modeling), which specifically focus on analyzing and modeling drug effects in the body. Overall, Certara's business model is designed to offer customers a comprehensive range of services and products to support drug development. By combining modeling and simulation strategies, regulatory science methods, and clinical pharmacology, the company provides its customers with a unique solution for optimizing drug development. With its portfolio of innovative products and services, Certara is a leader in the industry and sets the standard for the future of drug development.

odotettu liikevaihto Certara on 379,66 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Certara on 54,44 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Certara:n hinta-voitto-suhde (P/E) on tällä hetkellä 28,20. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Certara-osakkeen arvostusta.

Certara:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,04. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Certara-osakkeen arvostuskennuslukuna.

Certara:n Eulpool-laatuscore on 2/10.

Certara:n ISIN on US15687V1098. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Certara:n WKN on A2QJL8. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Certara:n ticker on CERT. Tämä pörssinoteeraus käytetään Certara-osakkeiden kauppaan pörssissä.